Drug Trial Radar · NCT04615156
18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography
Last checked: Nov 19, 2026Latest source record: Nov 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10,000
Planned (sponsor's estimate)
Start
Nov 1, 2020
Primary completion
Nov 1, 2027
Study completion Nov 1, 2027
Sponsor
- Lead sponsor
- Eastern Health, CanadaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study objectives are as follows: * To determine the safety of trial 18F-2-fluoro-2-deoxy-D-glucose, produced by a new manufacturer, by surveillance for adverse events in patients having Positron Emission Tomography Computed Tomography scans in a comprehensive program for indications including, but not limited to, oncology, neurology, cardiac and infectious/inflammatory processes. * To determine the efficacy of 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography in differentiating benign from malignant solitary pulmonary nodules and calculate sensitivity, specificity, and accuracy using pathologic confirmation as the gold standard when available, or greater than 6 month follow up stability on Computed Tomography scan when not. The purpose of performing this clinical trial is to provide local access of 18F-2-fluoro-2-deoxy-D-glucose to the patients of Newfoundland and Labrador. This product has been offered to patients over the last three years by transporting from facilities outside of the province. There have been significant delays in access and in fact, times where 18F-2-fluoro-2-deoxy-D-glucose has not been available through this process. This has caused delays and limitations of treatments for patients who rely on Positron Emission Tomography Computed Tomography scans for diagnosis.
Conditions
- Solitary Pulmonary Nodule
- Oncology
- 18F-2-fluoro-2-deoxy-D-glucose
- Adverse Event
Interventions
18F-2-fluoro-2-deoxy-D-glucoseDrug
Administration of 18F-2-fluoro-2-deoxy-D-glucose for the purposes of diagnosis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Measuring the safety of 18F-2-fluoro-2-deoxy-D-glucose produced by a new manufacturer by evaluating for any adverse events that occur during their Positron Emission Tomography Computed Tomography scan appointment.Time frame: For the length of time required to perform informed consent, the scan, and follow-up interview for adverse events, approximately 4 hours
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.